Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from HC Wainwright

The $6.6 Billion Reason CleanSpark Stock Is Up Today

CleanSpark stock soars on a major data center deal. But does that warrant buying CLSK shares at current levels?

Barchart

Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter

Fennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. Ram Selvaraju, managing dir

MarketBeat

The Shocking Reason This Analyst Says Michael Saylor and MicroStrategy Stock Will Take Bitcoin Prices to $0

Michael Saylor's goal of dominating Bitcoin may very well be the downfall of both MSTR stock and BTC.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

The Insider Report: Prepare for the Next Dip Buying Opportunity

The turbulence in stocks continued with the Nasdaq reeling from the tech wreck. It finished down 2.74%, while the Dow Jones Industrial Average and the SP 500 finished down 1.91% and 1.94%, respectively. The rotation into healthcare continues to accelerate, and it's really the only sector offering abundant and attractive…

Benzinga

What's Going On With BigBear.ai (BBAI) Stock Thursday?

BigBear.ai Holdings Inc (NYSE:BBAI) shares are trading lower Thursday morning, taking a breather after a multi-day surge fueled by a double-beat earnings report and a strategic acquisition. Despite the morning pullback, the AI solutions provider has generated optimism this week regarding its long-term growth trajectory.

Benzinga

SoundHound Stock Just Got a New Street-High Price Target. Should You Buy SOUN Here?

H.C. Wainwright analysts recently gave a Street-high price target to SoundHound.

Barchart

Coinbase Jumps On Big Q3 Beat As Analysts Back 'Everything Exchange' Push

Shares of Coinbase Global Inc. (NASDAQ:COIN) were trading higher on Friday after the company reported upbeat third-quarter results a day earlier.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

The Melt-Up in SoundHound AI Isn’t Over By a Long Shot

SoundHound AI's stock price is set up for a massive rally that could begin as soon as the Q3 earnings release in early November.

MarketBeat

Plug Power Just Named a New CEO. Should You Buy, Sell, or Hold PLUG Stock Here?

Plug Power is back in the spotlight with fresh leadership news.

Barchart

Plug Power Just Got a New Street-High Price Target. Should You Buy PLUG Stock Here?

Plug Power received a Street-high price target from H.C. Wainwright. Should you buy PLUG stock?

Barchart

Plug Power Stock Hits New 52-Week Highs: What's Fueling The Momentum?

Shares of Plug Power Inc (NASDAQ:PLUG) are surging Monday morning, continuing a powerful rally that has seen the hydrogen fuel-cell company's stock climb 160% over the past month. Here’s what investors need to know.

Benzinga

This AI Stock Has More Than Doubled in 2025. Is It a Buy?

After a remarkable triple-digit surge so far in 2025, is now the time to buy the shares of this AI stock?

Barchart

Voyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: Analyst

Last week, HC Wainwright hosted Voyager Therapeutics, Inc.’s (NASDAQ:VYGR) management during HCW's Annual Global Investment Conference.

Benzinga

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Summit Therapeutics Inc (NASDAQ:SMMT) and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

The global biopharmaceutical landscape is rapidly evolving, driven by innovations targeting complex diseases like organ fibrosis and liver conditions. As companies push the boundaries of medical science, new therapies are emerging that promise to transform patient care and redefine market leadership in these critical areas.

Barchart

Down 50% From Its Highs, This Analyst Thinks CoreWeave Stock Can Double From Here

CoreWeave’s sharp pullback may be setting the stage for a powerful rebound, according to H.C. Wainwright.

Barchart

1 Analyst Says the Selloff in CoreWeave Stock is Overdone. Is CRWV Stock a Buy Here?

CRWV is testing a Fibonacci retracement level on the charts after an upgrade from H.C. Wainwright and reports that Jane Street bought a 5.4% stake.

MarketBeat

Who Won and Who Lost in Nuclear Energy’s Q2 Earnings

From industry leaders to pre-revenue innovators, see which well-known nuclear energy stocks had the best and worst earnings performances in Q2.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Catalysts Align: Archer Beats Estimates, Delivers Aircraft to UAE

Archer Aviation's strong Q2 results, highlighted by its first UAE aircraft delivery and a strong balance sheet, reinforce its path to near-term revenue.

Benzinga

CoreWeave's AI Demand Surges But Expansion Spending Cuts Into Profitability

CoreWeave (NASDAQ:CRWV) shares tumbled on Wednesday after the AI-focused cloud computing provider posted mixed second-quarter results, highlighting surging revenue and backlog alongside margin pressures from an aggressive expansion plan.

Benzinga

Archer Aviation Q2 Disappoints: First Revenue Stream In Sight?

Shares of Archer Aviation Inc (NYSE:ACHR) recorded gains in trading on Tuesday, despite a downbeat second-quarter report.

Barchart

Why Morgan Stanley Upgraded This Biotech Stock to a Buy

Ionis is shaping up to be one of the most compelling long-term growth stories in biotech today.

Benzinga

Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks

HC Wainwright assumed coverage on Ultragenyx Pharmaceuticals, Inc. (NASDAQ:RARE) on Monday, representing an attractive opportunity at current levels.

Barchart

Why This Analyst Thinks MicroStrategy Stock Can Soar to a New Street-High Target of $680

TD Cowen believes MSTR can reach $680. Will shares hit that mark?

Barchart

This Underdog AI Stock Just Got a New Street-High Price Target

This underrated AI player just landed a fresh price target on Wall Street as its AI-driven defense technology draws investor interest.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.